- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01170663
A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma (RAINBOW)
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is to determine if paclitaxel given together with ramucirumab (IMC-1211B) as second line therapy will prolong overall survival (OS) compared to paclitaxel alone.
Approximately 663 participants (at least 18 years) in approximately 200 study centers and in approximately 30 countries will be randomized with histologically or cytologically confirmed metastatic gastric or gastroesophageal junction adenocarcinoma. Participants must have received at least one cycle of first line therapy with any platinum/fluoropyrimidine doublet with or without anthracycline (epirubicin or doxorubicin) and must have discontinued this therapy prior to study entry due to disease progression.
Upon registration and completion of screening procedure and reviewing the Inclusion and Exclusion Criteria eligible participants will be randomized to receive either paclitaxel plus ramucirumab or paclitaxel plus placebo.
Ramucirumab (IMC-1211B) DP/placebo will be administered IV on Days 1 and 15, paclitaxel will be administered IV on Days 1, 8 and 15 of a 4 weekly cycle.
Participants will be continuously treated and monitored until radiographic or symptomatic progression of disease, toxicity requiring cessation, protocol noncompliance, or withdrawal of consent.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, C1019ABS
- ImClone Investigational Site
-
Caba, Argentina, C1050AAK
- ImClone Investigational Site
-
Rosario, Argentina, 2000
- ImClone Investigational Site
-
Santa Fe, Argentina, 3000
- ImClone Investigational Site
-
-
-
-
New South Wales
-
Bankstown, New South Wales, Australia, 2200
- ImClone Investigational Site
-
Kogarah, New South Wales, Australia, 2217
- ImClone Investigational Site
-
Liverpool, New South Wales, Australia, 2170
- ImClone Investigational Site
-
Wollongong, New South Wales, Australia, 2500
- ImClone Investigational Site
-
-
Queensland
-
Southport, Queensland, Australia, 4215
- ImClone Investigational Site
-
-
South Australia
-
Kurralta Park, South Australia, Australia, 5037
- ImClone Investigational Site
-
-
Victoria
-
Coburg, Victoria, Australia, 3058
- ImClone Investigational Site
-
Footscray, Victoria, Australia, 3011
- ImClone Investigational Site
-
Frankston, Victoria, Australia, 3199
- ImClone Investigational Site
-
Parkville, Victoria, Australia, 3050
- ImClone Investigational Site
-
-
-
-
-
Graz, Austria, 8036
- ImClone Investigational Site
-
Linz, Austria, A-4010
- ImClone Investigational Site
-
Steyr, Austria, 4400
- ImClone Investigational Site
-
Vienna, Austria, 1100
- ImClone Investigational Site
-
-
-
-
-
Bonheiden, Belgium, 2820
- ImClone Investigational Site
-
Brugge, Belgium, 8310
- ImClone Investigational Site
-
Brussels, Belgium, 1000
- ImClone Investigational Site
-
Brussels, Belgium, 1070
- ImClone Investigational Site
-
Edegem, Belgium, 2650
- ImClone Investigational Site
-
Leuven, Belgium, 3000
- ImClone Investigational Site
-
-
-
-
-
Belo Horizonte, Brazil, 30130-100
- ImClone Investigational Site
-
Belo Horizonte, Brazil, 30150-281
- ImClone Investigational Site
-
Caxias Do Sul, Brazil, 95070560
- ImClone Investigational Site
-
Dois Lajeados, Brazil, 95900-000
- ImClone Investigational Site
-
Gavea, Brazil, 22451-010
- ImClone Investigational Site
-
Ijui, Brazil, 98700 000
- ImClone Investigational Site
-
Itajai, Brazil, 88301-170
- ImClone Investigational Site
-
Londrina, Brazil, 86050-190
- ImClone Investigational Site
-
Passo Fundo, Brazil, 99010-260
- ImClone Investigational Site
-
Porto Alegre, Brazil, 90035-903
- ImClone Investigational Site
-
Porto Alegre-Rs, Brazil, 90020090
- ImClone Investigational Site
-
Ribeirão Preto, Brazil, 14015-130
- ImClone Investigational Site
-
Rio De Janeiro, Brazil, 20231-050
- ImClone Investigational Site
-
Salvador, Brazil, 41820-021
- ImClone Investigational Site
-
Sao Jose Rio Preto, Brazil, 15090-000
- ImClone Investigational Site
-
Sorocaba, Brazil, 18031-000
- ImClone Investigational Site
-
São Paulo, Brazil, 01246-000
- ImClone Investigational Site
-
São Paulo, Brazil, 04122-000
- ImClone Investigational Site
-
São Paulo, Brazil
- ImClone Investigational Site
-
-
-
-
-
Sofia, Bulgaria, 1756
- ImClone Investigational Site
-
Varna, Bulgaria, 9000
- ImClone Investigational Site
-
-
-
-
-
Providencia, Chile
- ImClone Investigational Site
-
Vina Del Mar, Chile
- ImClone Investigational Site
-
-
-
-
-
Tallinn, Estonia, 10138
- ImClone Investigational Site
-
Tallinn, Estonia, 13419
- ImClone Investigational Site
-
-
-
-
-
Besancon, France, 25030
- ImClone Investigational Site
-
Brest, France, 29609
- ImClone Investigational Site
-
Clermont-Ferrand, France, 63003
- ImClone Investigational Site
-
Marseille, France, 13385
- ImClone Investigational Site
-
Montbeliard, France, 25200
- ImClone Investigational Site
-
Montpellier, France, 34298
- ImClone Investigational Site
-
Paris, France, 75013
- ImClone Investigational Site
-
Paris, France, 75015
- ImClone Investigational Site
-
Paris, France, 75475
- ImClone Investigational Site
-
Saint-Etienne, France, 42055
- ImClone Investigational Site
-
-
-
-
-
Berlin, Germany, 13353
- ImClone Investigational Site
-
Bielefeld, Germany, 33611
- ImClone Investigational Site
-
Dresden, Germany, 01307
- ImClone Investigational Site
-
Essen, Germany, 45136
- ImClone Investigational Site
-
Frankfurt, Germany, 60596
- ImClone Investigational Site
-
Hamburg, Germany, 22087
- ImClone Investigational Site
-
Heidelberg, Germany, 69115
- ImClone Investigational Site
-
Leipzig, Germany, 04103
- ImClone Investigational Site
-
Mainz, Germany, 55131
- ImClone Investigational Site
-
Munich, Germany, 81737
- ImClone Investigational Site
-
Recklinghausen, Germany, 45657
- ImClone Investigational Site
-
Tuebingen, Germany, 72076
- ImClone Investigational Site
-
-
-
-
-
Budapest, Hungary, 1125
- ImClone Investigational Site
-
Gyula, Hungary, 5700
- ImClone Investigational Site
-
Kaposvar, Hungary, 7400
- ImClone Investigational Site
-
Pecs, Hungary, 7624
- ImClone Investigational Site
-
Szekesfehervar, Hungary, 8000
- ImClone Investigational Site
-
-
-
-
-
Beer Sheva, Israel, 84101
- ImClone Investigational Site
-
Haifa, Israel, 31096
- ImClone Investigational Site
-
Holon, Israel, 58100
- ImClone Investigational Site
-
Jerusalem, Israel, 91120
- ImClone Investigational Site
-
Petah Tikva, Israel, 49100
- ImClone Investigational Site
-
Tel Hashomer, Israel, 52661
- ImClone Investigational Site
-
Tel-Aviv, Israel, 64239
- ImClone Investigational Site
-
-
-
-
-
Ancona, Italy, 60100
- ImClone Investigational Site
-
Bari, Italy, 70126
- ImClone Investigational Site
-
Bergamo, Italy, 24125
- ImClone Investigational Site
-
Catania, Italy, 95122
- ImClone Investigational Site
-
Genova, Italy, 16132
- ImClone Investigational Site
-
Milano, Italy, 20121
- ImClone Investigational Site
-
Padova, Italy, 35128
- ImClone Investigational Site
-
Pisa, Italy, 56126
- ImClone Investigational Site
-
Torino, Italy, 10100
- ImClone Investigational Site
-
-
-
-
-
Aichi, Japan, 464
- ImClone Investigational Site
-
Chiba, Japan, 277 8577
- ImClone Investigational Site
-
Ehime, Japan, 790-0007
- ImClone Investigational Site
-
Fukuoka, Japan, 811-1395
- ImClone Investigational Site
-
Hokkaido, Japan, 060-0814
- ImClone Investigational Site
-
Kochi, Japan, 781-8555
- ImClone Investigational Site
-
Oita, Japan, 8795593
- ImClone Investigational Site
-
Osaka, Japan, 569-8686
- ImClone Investigational Site
-
Osaka-Pref, Japan, 589
- ImClone Investigational Site
-
Saitama, Japan, 362-0806
- ImClone Investigational Site
-
Shizuoka, Japan, 411-8777
- ImClone Investigational Site
-
Tochigi, Japan, 320-0834
- ImClone Investigational Site
-
Tokyo, Japan, 181-8611
- ImClone Investigational Site
-
-
-
-
-
Incheon, Korea, Republic of, 405-760
- ImClone Investigational Site
-
Seongnam-Si, Korea, Republic of, 463-707
- ImClone Investigational Site
-
Seoul, Korea, Republic of, 110-744
- ImClone Investigational Site
-
Suwon, Korea, Republic of, 443-721
- ImClone Investigational Site
-
Suwon-City, Korea, Republic of, 442-723
- ImClone Investigational Site
-
-
-
-
-
Kaunas, Lithuania, LT-50009
- ImClone Investigational Site
-
Klaipeda, Lithuania, LT-92288
- ImClone Investigational Site
-
-
-
-
-
Juchitan, Mexico, 70000
- ImClone Investigational Site
-
Nuevo Leon, Mexico, 64060
- ImClone Investigational Site
-
-
-
-
-
Brzozow, Poland, 36-200
- ImClone Investigational Site
-
Bydgoszcz, Poland, 85-769
- ImClone Investigational Site
-
Gdansk, Poland, 80-210
- ImClone Investigational Site
-
Lodz, Poland, 93-509
- ImClone Investigational Site
-
Lublin, Poland, 20-090
- ImClone Investigational Site
-
Poznan, Poland, 61- 485
- ImClone Investigational Site
-
Warsaw, Poland, 02-781
- ImClone Investigational Site
-
-
-
-
-
Aveiro, Portugal, 3814-501
- ImClone Investigational Site
-
Coimbra, Portugal, 3001-651
- ImClone Investigational Site
-
Evora, Portugal, 7000-811
- ImClone Investigational Site
-
Porto, Portugal, 4202-451
- ImClone Investigational Site
-
Santa Maria Da Feira, Portugal, 4520-211
- ImClone Investigational Site
-
-
-
-
-
Baia Mare, Romania, 430031
- ImClone Investigational Site
-
Bucharest, Romania
- ImClone Investigational Site
-
Iasi, Romania, 700106
- ImClone Investigational Site
-
Targu Mures, Romania, 540072
- ImClone Investigational Site
-
-
-
-
-
Krasnodar, Russian Federation, 350040
- ImClone Investigational Site
-
Moscow, Russian Federation, 115478
- ImClone Investigational Site
-
Perm, Russian Federation, 614066
- ImClone Investigational Site
-
Saint Petersburg, Russian Federation, 191025
- ImClone Investigational Site
-
Ufa, Russian Federation, 450054
- ImClone Investigational Site
-
-
-
-
-
Singapore, Singapore, 258499
- ImClone Investigational Site
-
-
-
-
-
Avila, Spain, 05004
- ImClone Investigational Site
-
Burgos, Spain, 9005
- ImClone Investigational Site
-
Jerez De La Frontera, Spain, 11407
- ImClone Investigational Site
-
Madrid, Spain, 28041
- ImClone Investigational Site
-
Majadahonda, Spain, 28222
- ImClone Investigational Site
-
Palma De Mallorca, Spain, 07014
- ImClone Investigational Site
-
Sabadell, Spain, 08208
- ImClone Investigational Site
-
Sevilla, Spain, 41009
- ImClone Investigational Site
-
-
-
-
-
Changhua, Taiwan, 500
- ImClone Investigational Site
-
Kaohsiung, Taiwan, 833
- ImClone Investigational Site
-
Liouying/Tainan, Taiwan, 736
- ImClone Investigational Site
-
Taichung, Taiwan, 404
- ImClone Investigational Site
-
Tainan, Taiwan, 70403
- ImClone Investigational Site
-
Taipei, Taiwan, 112
- ImClone Investigational Site
-
-
-
-
Kent
-
Maidstone, Kent, United Kingdom, ME16 9QQ
- ImClone Investigational Site
-
-
Surrey
-
Guildford, Surrey, United Kingdom, GU2 7XX
- ImClone Investigational Site
-
Sutton, Surrey, United Kingdom, SM2 5PT
- ImClone Investigational Site
-
-
West Midlands
-
Wolverhampton, West Midlands, United Kingdom, WV10 0QP
- ImClone Investigational Site
-
-
-
-
California
-
Burbank, California, United States, 91505
- ImClone Investigational Site
-
Los Angeles, California, United States, 90095
- ImClone Investigational Site
-
San Francisco, California, United States, 94115
- ImClone Investigational Site
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- ImClone Investigational Site
-
Miramar, Florida, United States, 33027
- ImClone Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- ImClone Investigational Site
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- ImClone Investigational Site
-
-
New Jersey
-
East Orange, New Jersey, United States, 07018
- ImClone Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- ImClone Investigational Site
-
-
New York
-
New York, New York, United States, 10016
- ImClone Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- ImClone Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- ImClone Investigational Site
-
-
Washington
-
Seattle, Washington, United States, 98109
- ImClone Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma
- Metastatic disease or locally advanced, unresectable disease
- Disease progression during or within 4 months after the last dose of the first-line therapy (platinum/fluoropyrimidine doublet with or without anthracycline)
- Organs are functioning well (liver, kidney, blood)
- Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 1
Exclusion Criteria:
- First line chemotherapy for metastatic gastric cancer other than platinum/fluoropyrimidine doublet with or without anthracycline
- Previous systemic therapy with other anti-angiogenic drugs
- Uncontrolled high blood pressure
- Symptomatic or poorly controlled heart disease or had a heart attack or stroke within the last 6 month
- Evidence of central nervous system (CNS) metastasis at baseline
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel
Ramucirumab (IMC-1211B) DP and Paclitaxel
|
8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
Other Names:
Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
|
Placebo Comparator: Placebo and Paclitaxel
|
Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival Time (OS)
Time Frame: Randomization up to 27.5 months
|
OS time was measured from date of randomization to date of death from any cause.
Participants who were not known to have died on or before the date of data cut-off, OS data was censored on the last date (on or before the cut-off date) the participant was known to be alive.
|
Randomization up to 27.5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: Randomization up to 22.2 months
|
PFS was measured from date of randomization to first radiographically documented progressive disease (PD) or death due to any cause.
PD defined using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) as ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study).
The sum must also demonstrate an absolute increase of at least 5 mm.
Participants who had no baseline or post baseline radiological tumor assessment were censored at date of randomization.
Participants who had no tumor progression or death within 2 scan intervals following the last assessment were censored at the date of last radiographic tumor assessment.
Participants who began new anticancer treatment and had no tumor progression were censored at date of assessment prior to initiation of new therapy.
Participants lost to follow-up or withdrew consent were censored at the date of their last assessment.
|
Randomization up to 22.2 months
|
Time to Progressive Disease (TTP)
Time Frame: Baseline up to 22.2 months
|
TTP was defined as the time from randomization until date of radiographic progression using RECIST v1.1 criteria.
PD was defined as having a ≥20% increase in sum of longest diameter (LD) of target lesions and at minimum 5 millimeters (mm) increase above nadir.
Participants who did not progress or were lost to follow-up were censored at the date of last tumor assessment.
Participants who had no baseline tumor assessment or no post baseline assessment and no death reported with 2 scan intervals post randomization were censored at date of randomization.
Participants with no progression and not died within 2 scan intervals after last assessment were censored at date of last tumor assessment.
Participants with no post baseline assessment or tumor progression but death reported within 2 scan intervals after randomization were censored at date of death.
|
Baseline up to 22.2 months
|
Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or PD
Time Frame: Randomization up to 22.2 months
|
BOR was defined as the best response across all time points from randomization until radiologically confirmed PD using RECIST, v1.1 criteria.
CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and normalization of tumor marker level of non-target lesions.
PR was defined as having a ≥30% decrease in sum of LD of target lesions.
PD was defined as having a ≥20% increase in sum of LD of target lesions and ≥5 mm increase above nadir.
SD was defined as small changes that did not meet above criteria.
|
Randomization up to 22.2 months
|
Percentage of Participants With CR or PR (Objective Response Rate [ORR])
Time Frame: Randomization up to 22.2 months
|
ORR was the percentage of participants who had CR or PR defined using RECIST v1.1 criteria.
CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and normalization of tumor marker level of non-target lesions.
PR was defined as having a ≥30% decrease in sum of LD of target lesions.
Percentage of participants calculated as: (number of participants with CR + PR)/(total number of participants)*100.
|
Randomization up to 22.2 months
|
Percentage of Participants With Anti-Ramucirumab Antibodies (Serum Anti-Ramucirumab Antibody Assessment )(Immunogenicity)
Time Frame: Prior to and after ramucirumab (IMC-1121B) infusion: Day 1 Cycles 1, 2 and 3 (28-day cycles) Doses 1, 4, 7 and 30-37 days after last dose of study therapy up to 103 weeks
|
Participants who developed treatment-emergent antibody responses to Ramucirumab (IMC-1121B) after baseline.
|
Prior to and after ramucirumab (IMC-1121B) infusion: Day 1 Cycles 1, 2 and 3 (28-day cycles) Doses 1, 4, 7 and 30-37 days after last dose of study therapy up to 103 weeks
|
Maximum Concentration (Cmax) After First Ramucirumab (IMC-1211B) Infusion
Time Frame: Cycle 1, Day 1, 1 hour post end of infusion (28-day cycles)
|
Cycle 1, Day 1, 1 hour post end of infusion (28-day cycles)
|
|
Cmax After 4th Ramucirumab (IMC-1211B) Infusion
Time Frame: Cycle 2, Day 15 1 hour post end of infusion (28-day cycles)
|
Cycle 2, Day 15 1 hour post end of infusion (28-day cycles)
|
|
Cmax After 7th Ramucirumab (IMC-1211B) Infusion
Time Frame: Cycle 4, Day 1, 1 hour post end of infusion (28-day cycles)
|
Cycle 4, Day 1, 1 hour post end of infusion (28-day cycles)
|
|
Minimum Concentration (Cmin) Prior to First Ramucirumab (IMC-1211B) Infusion
Time Frame: Cycle 1, Day 1 predose (28-day cycles)
|
This outcome measure was included in error as the time point was before ramucirumab (IMC-1211B) was administered.
Cmin was not analyzed.
|
Cycle 1, Day 1 predose (28-day cycles)
|
Cmin Prior to 4th Ramucirumab (IMC-1211B) Infusion
Time Frame: Cycle 2, Day 15 (28-day cycle)
|
Cycle 2, Day 15 (28-day cycle)
|
|
Cmin Prior to 7th Ramucirumab (IMC-1211B) Infusion
Time Frame: Cycle 4, Day 1 (28-day cycles)
|
Cycle 4, Day 1 (28-day cycles)
|
|
Change From Baseline to End of Therapy in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life: Questionnaire (QLQ-C30) in Global Health Status
Time Frame: Baseline, end of therapy (up to 103 weeks)
|
EORTC QLQ-C30 v3.0 is a 30-item, self-administered questionnaire with multidimensional scales assessing 15 domains (5 functional domains [physical, role, cognitive, emotional, and social], 9 symptom scales [fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties] and global health status scale).
28 questions assessed on a 1 (not at all) to 4 (very much) scale and the remaining 2 questions used a 1 (poor) to 7 (excellent) scale.
A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines.
For the functional domains and global health status scale, higher scores represent a better level of functioning.
For symptoms scales, higher scores represented a greater degree of symptoms.
|
Baseline, end of therapy (up to 103 weeks)
|
Change From Baseline to End of Therapy in European Quality of Life Questionnaire-5 Dimension (EuroQol EQ-5D) Index Score
Time Frame: Baseline, end of therapy (up to 103 weeks)
|
The EQ-5D is a generic, multidimensional, health status instrument.
The profile allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale [1 (no problem), 2 (some problems), and 3 (major problems)].
These combinations of responses were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm.
The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).
A negative change indicated a worsening of the participant's health status.
|
Baseline, end of therapy (up to 103 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Serious and Other Non-serious Adverse Events (AE) and Who Died
Time Frame: Baseline up to 103 weeks and within 30 days of last dose of study drug
|
Participants who died or who had clinically significant events defined as serious AEs (SAEs) and other non-serious AEs (regardless of causality).
A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
|
Baseline up to 103 weeks and within 30 days of last dose of study drug
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Mitani S, Chen Y, Inoue K, Mori J, Gao L, Long A, Wakabayashi S. Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach. Gan To Kagaku Ryoho. 2021 Nov;48(11):1381-1387.
- Yamaguchi K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, Nishina T, Omuro Y, Tamura T, Piao Y, Homma G, Jen MH, Liepa AM, Muro K. Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial. Clin Drug Investig. 2021 Jan;41(1):53-64. doi: 10.1007/s40261-020-00979-3. Epub 2020 Dec 23.
- Cascinu S, Bodoky G, Muro K, Van Cutsem E, Oh SC, Folprecht G, Ananda S, Girotto G, Wainberg ZA, Miron MLL, Ajani J, Wei R, Liepa AM, Carlesi R, Emig M, Ohtsu A. Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. Oncologist. 2021 Mar;26(3):e414-e424. doi: 10.1002/onco.13623. Epub 2020 Dec 23.
- De Vita F, Borg C, Farina G, Geva R, Carton I, Cuku H, Wei R, Muro K. Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. Future Oncol. 2019 Aug;15(23):2723-2731. doi: 10.2217/fon-2019-0243. Epub 2019 Jun 25. Erratum In: Future Oncol. 2021 Sep;17(25):3409.
- Chau I, Fuchs CS, Ohtsu A, Barzi A, Liepa AM, Cui ZL, Hsu Y, Al-Batran SE. Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. Eur J Cancer. 2019 Jan;107:115-123. doi: 10.1016/j.ejca.2018.11.013. Epub 2018 Dec 14.
- Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther. 2017 Oct;16(10):2215-2222. doi: 10.1158/1535-7163.MCT-16-0895. Epub 2017 Jul 17.
- Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. Ann Oncol. 2016 Apr;27(4):673-9. doi: 10.1093/annonc/mdv625. Epub 2016 Jan 7.
- Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, Nishina T, Yamaguchi K, Segawa Y, Omuro Y, Tamura T, Doi T, Yukisawa S, Yasui H, Nagashima F, Gotoh M, Esaki T, Emig M, Chandrawansa K, Liepa AM, Wilke H, Ichimiya Y, Ohtsu A. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer. 2016 Jul;19(3):927-38. doi: 10.1007/s10120-015-0559-z. Epub 2015 Oct 28.
- Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13894
- I4T-IE-JVBE (Other Identifier: Eli Lilly and Company)
- CP12-0922 (Other Identifier: ImClone Systems)
- 2010-020426-18 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Clinical Study Report (CSR)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingHereditary Diffuse Gastric CancerFrance
Clinical Trials on Ramucirumab (IMC-1211B) DP
-
Eli Lilly and CompanyCompletedHepatocellular CarcinomaUnited States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedCarcinoma of Urinary Tract | Urethral Carcinoma | Carcinoma of Ureter | Carcinoma of Renal PelvisUnited States, Canada
-
Eli Lilly and CompanyCompletedHepatocellular CarcinomaUnited States
-
Eli Lilly and CompanyParexelCompleted
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyNo longer availableMetastatic Gastric Cancer | Metastatic Adenocarcinoma of the Gastroesophageal JunctionGermany, Netherlands, Austria, Greece, Korea, Republic of
-
Eli Lilly and CompanyCompletedBreast CancerUnited States, Canada, Australia, Belgium, Brazil, Croatia, Czechia, Egypt, Germany, Ireland, Israel, Korea, Republic of, Lebanon, New Zealand, Peru, Poland, Russian Federation, Serbia, Slovakia, South Africa, Spain, Taiwan, United...
-
Eli Lilly and CompanyCompletedGastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States, Poland, Romania, Hungary, Russian Federation, Australia, France, Argentina, United Kingdom, New Zealand, Turkey, Slovakia
-
Eli Lilly and CompanyCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CarcinomaUnited States, United Kingdom